Literature Collection

Collection Insights

10K+

References

9K+

Articles

1400+

Grey Literature

4500+

Opioids & SU

The Literature Collection contains over 10,000 references for published and grey literature on the integration of behavioral health and primary care. Learn More

Use the Search feature below to find references for your terms across the entire Literature Collection, or limit your searches by Authors, Keywords, or Titles and by Year, Type, or Topic. View your search results as displayed, or use the options to: Show more references per page; Sort references by Title or Date; and Refine your search criteria. Expand an individual reference to View Details. Full-text access to the literature may be available through a link to PubMed, a DOI, or a URL. References may also be exported for use in bibliographic software (e.g., EndNote, RefWorks, Zotero).

Year
Sort by
Order
Show
511 Results
321
Opioid-Overdose Reduction Continuum of Care Approach (ORCCA): A Policymakers Guide to Implementing Evidence-Based Strategies that Address Opioid Overdose
Type: Government Report
Authors: National Institutes of Health HEAL Initiative
Year: 2023
Publication Place: Bethesda, MD
Topic(s):
Grey Literature See topic collection
,
Healthcare Policy See topic collection
,
Opioids & Substance Use See topic collection
Disclaimer:

This grey literature reference is included in the Academy's Literature Collection in keeping with our mission to gather all sources of information on integration. Grey literature is comprised of materials that are not made available through traditional publishing avenues. Often, the information from unpublished resources can be limited and the risk of bias cannot be determined.

322
Opioid‐related overdose deaths among people experiencing homelessness, 2017 to 2021: A population‐based analysis using coroner and health administrative data from Ontario, Canada
Type: Journal Article
Authors: Richard G. Booth, Salimah Z. Shariff, Brooke Carter, Stephen W. Hwang, Aaron M. Orkin, Cheryl Forchuk, Tara Gomes
Year: 2024
Topic(s):
Opioids & Substance Use See topic collection
,
Healthcare Disparities See topic collection
323
Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used WHO Step III opioids
Type: Journal Article
Authors: J. Pergolizzi, R. H. Boger, K. Budd, A. Dahan, S. Erdine, G. Hans, H. G. Kress, R. Langford, R. Likar, R. B. Raffa, P. Sacerdote
Year: 2008
Publication Place: United States
Abstract: SUMMARY OF CONSENSUS: 1. The use of opioids in cancer pain: The criteria for selecting analgesics for pain treatment in the elderly include, but are not limited to, overall efficacy, overall side-effect profile, onset of action, drug interactions, abuse potential, and practical issues, such as cost and availability of the drug, as well as the severity and type of pain (nociceptive, acute/chronic, etc.). At any given time, the order of choice in the decision-making process can change. This consensus is based on evidence-based literature (extended data are not included and chronic, extended-release opioids are not covered). There are various driving factors relating to prescribing medication, including availability of the compound and cost, which may, at times, be the main driving factor. The transdermal formulation of buprenorphine is available in most European countries, particularly those with high opioid usage, with the exception of France; however, the availability of the sublingual formulation of buprenorphine in Europe is limited, as it is marketed in only a few countries, including Germany and Belgium. The opioid patch is experimental at present in U.S.A. and the sublingual formulation has dispensing restrictions, therefore, its use is limited. It is evident that the population pyramid is upturned. Globally, there is going to be an older population that needs to be cared for in the future. This older population has expectations in life, in that a retiree is no longer an individual who decreases their lifestyle activities. The "baby-boomers" in their 60s and 70s are "baby zoomers"; they want to have a functional active lifestyle. They are willing to make trade-offs regarding treatment choices and understand that they may experience pain, providing that can have increased quality of life and functionality. Therefore, comorbidities--including cancer and noncancer pain, osteoarthritis, rheumatoid arthritis, and postherpetic neuralgia--and patient functional status need to be taken carefully into account when addressing pain in the elderly. World Health Organization step III opioids are the mainstay of pain treatment for cancer patients and morphine has been the most commonly used for decades. In general, high level evidence data (Ib or IIb) exist, although many studies have included only few patients. Based on these studies, all opioids are considered effective in cancer pain management (although parts of cancer pain are not or only partially opioid sensitive), but no well-designed specific studies in the elderly cancer patient are available. Of the 2 opioids that are available in transdermal formulation--fentanyl and buprenorphine--fentanyl is the most investigated, but based on the published data both seem to be effective, with low toxicity and good tolerability profiles, especially at low doses. 2. The use of opioids in noncancer-related pain: Evidence is growing that opioids are efficacious in noncancer pain (treatment data mostly level Ib or IIb), but need individual dose titration and consideration of the respective tolerability profiles. Again no specific studies in the elderly have been performed, but it can be concluded that opioids have shown efficacy in noncancer pain, which is often due to diseases typical for an elderly population. When it is not clear which drugs and which regimes are superior in terms of maintaining analgesic efficacy, the appropriate drug should be chosen based on safety and tolerability considerations. Evidence-based medicine, which has been incorporated into best clinical practice guidelines, should serve as a foundation for the decision-making processes in patient care; however, in practice, the art of medicine is realized when we individualize care to the patient. This strikes a balance between the evidence-based medicine and anecdotal experience. Factual recommendations and expert opinion both have a value when applying guidelines in clinical practice. 3. The use of opioids in neuropathic pain: The role of opioids in neuropathic pain has been under debate in the past but is nowadays more and more accepted; however, higher opioid doses are often needed for neuropathic pain than for nociceptive pain. Most of the treatment data are level II or III, and suggest that incorporation of opioids earlier on might be beneficial. Buprenorphine shows a distinct benefit in improving neuropathic pain symptoms, which is considered a result of its specific pharmacological profile. 4. The use of opioids in elderly patients with impaired hepatic and renal function: Functional impairment of excretory organs is common in the elderly, especially with respect to renal function. For all opioids except buprenorphine, half-life of the active drug and metabolites is increased in the elderly and in patients with renal dysfunction. It is, therefore, recommended that--except for buprenorphine--doses be reduced, a longer time interval be used between doses, and creatinine clearance be monitored. Thus, buprenorphine appears to be the top-line choice for opioid treatment in the elderly. 5. Opioids and respiratory depression: Respiratory depression is a significant threat for opioid-treated patients with underlying pulmonary condition or receiving concomitant central nervous system (CNS) drugs associated with hypoventilation. Not all opioids show equal effects on respiratory depression: buprenorphine is the only opioid demonstrating a ceiling for respiratory depression when used without other CNS depressants. The different features of opioids regarding respiratory effects should be considered when treating patients at risk for respiratory problems, therefore careful dosing must be maintained. 6. Opioids and immunosuppression: Age is related to a gradual decline in the immune system: immunosenescence, which is associated with increased morbidity and mortality from infectious diseases, autoimmune diseases, and cancer, and decreased efficacy of immunotherapy, such as vaccination. The clinical relevance of the immunosuppressant effects of opioids in the elderly is not fully understood, and pain itself may also cause immunosuppression. Providing adequate analgesia can be achieved without significant adverse events, opioids with minimal immunosuppressive characteristics should be used in the elderly. The immunosuppressive effects of most opioids are poorly described and this is one of the problems in assessing true effect of the opioid spectrum, but there is some indication that higher doses of opioids correlate with increased immunosuppressant effects. Taking into consideration all the very limited available evidence from preclinical and clinical work, buprenorphine can be recommended, while morphine and fentanyl cannot. 7. Safety and tolerability profile of opioids: The adverse event profile varies greatly between opioids. As the consequences of adverse events in the elderly can be serious, agents should be used that have a good tolerability profile (especially regarding CNS and gastrointestinal effects) and that are as safe as possible in overdose especially regarding effects on respiration. Slow dose titration helps to reduce the incidence of typical initial adverse events such as nausea and vomiting. Sustained release preparations, including transdermal formulations, increase patient compliance.
Topic(s):
Opioids & Substance Use See topic collection
,
Healthcare Disparities See topic collection
324
Opportunities for clinicians and health systems to address disparities in US drug overdose deaths by race and ethnicity
Type: Journal Article
Authors: Margaret Kirkegaard, Bren Manaugh
Year: 2023
Topic(s):
Education & Workforce See topic collection
,
Healthcare Disparities See topic collection
325
Opportunities To Address Overdose in Treatment
Type: Report
Authors: Education & Training in Addiction Institute for Research
Year: 2018
Topic(s):
Grey Literature See topic collection
,
Opioids & Substance Use See topic collection
Disclaimer:

This grey literature reference is included in the Academy's Literature Collection in keeping with our mission to gather all sources of information on integration. Grey literature is comprised of materials that are not made available through traditional publishing avenues. Often, the information from unpublished resources can be limited and the risk of bias cannot be determined.

326
Outcomes of a mobile medical unit for low-threshold buprenorphine access targeting opioid overdose hot spots in Chicago
Type: Journal Article
Authors: S. E. Messmer, A. T. Elmes, A. D. Jimenez, A. L. Murphy, M. Guzman, D. P. Watson, E. Poorman, S. Mayer, A. F. Infante, E. G. Keller, K. Whitfield, J. B. Jarrett
Year: 2023
Topic(s):
Opioids & Substance Use See topic collection
327
Overdose Alert and Response Technologies: State-of-the-art Review
Type: Journal Article
Authors: A. Oteo, H. Daneshvar, A. Baldacchino, C. Matheson
Year: 2023
328
Overdose Awareness
Type: Web Resource
Authors: Addiction Policy Forum
Year: 2021
Topic(s):
Grey Literature See topic collection
,
Opioids & Substance Use See topic collection
Disclaimer:

This grey literature reference is included in the Academy's Literature Collection in keeping with our mission to gather all sources of information on integration. Grey literature is comprised of materials that are not made available through traditional publishing avenues. Often, the information from unpublished resources can be limited and the risk of bias cannot be determined.

329
Overdose Death Rates
Type: Web Resource
Authors: National Institute on Drug Abuse
Year: 2019
Topic(s):
Grey Literature See topic collection
,
Opioids & Substance Use See topic collection
Disclaimer:

This grey literature reference is included in the Academy's Literature Collection in keeping with our mission to gather all sources of information on integration. Grey literature is comprised of materials that are not made available through traditional publishing avenues. Often, the information from unpublished resources can be limited and the risk of bias cannot be determined.

330
Overdose Deaths Declined but Remained Near Record Levels During the First Nine Months of 2022 as States Cope with Synthetic Opioids
Type: Report
Authors: Jesse C. Baumgartner, David C. Radley
Year: 2023
Publication Place: Washington, D.C.
Topic(s):
Opioids & Substance Use See topic collection
,
Grey Literature See topic collection
Disclaimer:

This grey literature reference is included in the Academy's Literature Collection in keeping with our mission to gather all sources of information on integration. Grey literature is comprised of materials that are not made available through traditional publishing avenues. Often, the information from unpublished resources can be limited and the risk of bias cannot be determined.

331
Overdose Deaths Involving Opioids, Cocaine, and Psychostimulants - United States, 2015-2016
Type: Journal Article
Authors: P. Seth, L. Scholl, R. A. Rudd, S. Bacon
Year: 2018
Abstract: During 1999?2015, 568,699 persons died from drug overdoses in the United States.* Drug overdose deaths in the United States increased 11.4% from 2014 to 2015 resulting in 52,404 deaths in 2015, including 33,091 (63.1%) that involved an opioid. The largest rate increases from 2014 to 2015 occurred among deaths involving synthetic opioids other than methadone (synthetic opioids) (72.2%) (1). Because of demographic and geographic variations in overdose deaths involving different drugs (2,3),� CDC examined age-adjusted death rates for overdoses involving all opioids, opioid subcategories (i.e., prescription opioids, heroin, and synthetic opioids),� cocaine, and psychostimulants with abuse potential (psychostimulants) by demographics, urbanization levels, and in 31 states and the District of Columbia (DC). There were 63,632 drug overdose deaths in 2016; 42,249 (66.4%) involved an opioid.� From 2015 to 2016, deaths increased across all drug categories examined. The largest overall rate increases occurred among deaths involving cocaine (52.4%) and synthetic opioids (100%), likely driven by illicitly manufactured fentanyl (IMF) (2,3). Increases were observed across demographics, urbanization levels, and states and DC. The opioid overdose epidemic in the United States continues to worsen. A multifaceted approach, with faster and more comprehensive surveillance, is needed to track emerging threats to prevent and respond to the overdose epidemic through naloxone availability, safe prescribing practices, harm-reduction services, linkage into treatment, and more collaboration between public health and public safety agencies.
Topic(s):
Opioids & Substance Use See topic collection
332
Overdose education and naloxone distribution for veterans with opioid use disorder: Results from a pilot initiative
Type: Journal Article
Authors: Grace Chang, Michelle Davids, Alan Kershaw
Year: 2017
Publication Place: England
Abstract:

Patients with opioid use disorder are at a high risk of overdose. To minimize that risk, a program offering intranasal naloxone rescue kits was piloted at a Veterans Administration Hospital. The purpose of this study was to characterize veterans who accepted these potentially lifesaving kits. Retrospective medical chart review of 158 veterans with opioid use disorder receiving treatment on either the inpatient psychiatry detoxification units or outpatient methadone maintenance setting who were offered overdose education and naloxone rescue kits. One hundred and ten of 158 veterans (70%) accepted overdose education and naloxone rescue. Overall, they had a mean age of 39.1 years and averaged 12.7 years of opioid use. In the prior month, they averaged 14.3 days of heroin use; they used alone 48.5% of the time. They estimated an average of 2.8 accidental overdoses over their lifetimes. There were few significant differences between those who accepted and those who declined with regard to demographic and clinical variables. However, significantly higher percentages of outpatients accepted overdose education and naloxone rescue compared to inpatients (89% versus 63%, p = 0.003, Chi-square); the odds of acceptance were increased four-fold when offered to outpatients. Outpatients were nearly a decade older, with more years of opioid use (19.0 versus 11.0), but with less utilization of inpatient services in the prior year (all p < 0.05). The main finding was that 70% of veterans accepted overdose education and naloxone rescue, but significantly higher proportions of outpatients were more receptive than inpatients (89% versus 63%, p = 0.003). Efforts to increase overdose education and naloxone rescue acceptance in all settings are encouraged.

Topic(s):
Education & Workforce See topic collection
,
Healthcare Disparities See topic collection
,
Opioids & Substance Use See topic collection
333
Overdose Education and Naloxone Distribution in the San Francisco County Jail
Type: Journal Article
Authors: Lynn D. Wenger, David Showalter, Barrot Lambdin, David Leiva, Eliza Wheeler, Peter J. Davidson, Phillip O. Coffin, Ingrid A. Binswanger, Alex H. Kral
Year: 2019
Publication Place: New Rochelle, New York
Topic(s):
Education & Workforce See topic collection
,
Healthcare Disparities See topic collection
,
Opioids & Substance Use See topic collection
334
Overdose Education and Naloxone Distribution Program Attendees: Who Attends, What Do They Know, and How Do They Feel?
Type: Journal Article
Authors: Sarah Cercone Heavey, Gale Burstein, Cheryll Moore, Gregory G. Homish
Year: 2018
Publication Place: United States
Abstract:

CONTEXT: The United States is in the midst of an opioid overdose epidemic. Opioids killed more than 28 000 people in 2014, more than any year on record. One approach to addressing this growing epidemic is Opioid Overdose Education and Naloxone Distribution (OEND) training. Little is known about these programs' participants and their effectiveness across different demographic groups. OBJECTIVES: To examine (1) whether knowledge and attitudes improved over the course of the training programs; (2) whether training outcomes differ by demographics; and (3) what overdose experiences do attendees have, and whether those experiences influence their knowledge and attitudes. DESIGN: A pre- and posttest survey was used to collect data on participants' demographics, overdose experiences, and opioid overdose knowledge and attitudes. SETTING: Surveys that took place at community-wide OEND programs were offered throughout Erie County, New York, during October and November 2015. PARTICIPANTS: Community members who elected to attend the training programs, were at least 18 years of age, spoke English, and were willing and able to participate were included in the sample (N = 198). INTERVENTION: N/A. MAIN OUTCOME MEASURE: The Opioid Overdose Knowledge and Attitudes Scale. RESULTS: Knowledge and attitude scores significantly improved from pre- to posttest assessments, increasing by 23.1% and 15.4%, respectively (Ps < .001). There were significant demographic differences in knowledge and attitudes at the pretest assessment, but these differences were ameliorated by the OEND program and did not persist at posttest assessment. In addition, 62.9% of participants had never experienced, witnessed, or known someone who had overdosed. CONCLUSION: Results indicate that OEND programs are effective at improving knowledge and attitudes toward opioid overdose. These results indicate that OEND programs are not reaching the highest risk individuals but are instead attracting concerned family and significant others. Future programs should focus on reaching current opioid users, overdose victims, and their families to ensure OEND programs are reaching the target audiences.

Topic(s):
Education & Workforce See topic collection
,
Measures See topic collection
,
Opioids & Substance Use See topic collection
335
Overdose education and naloxone distribution program design informed by people who use drugs and naloxone distributors
Type: Journal Article
Authors: M. Enich, R. Flumo, S. Campos, N. Flores, N. Sullivan, J. Mellor, C. O'Neill, A. N. Nyaku
Year: 2023
Topic(s):
Opioids & Substance Use See topic collection
,
Education & Workforce See topic collection
336
Overdose Experiences among People Who Inject Drugs in West Virginia: Personal Loss, Psychological Distress, Naloxone, and Fentanyl
Type: Journal Article
Authors: K. E. Schneider, S. T. Allen, A. K. Winiker, R. H. White, A. O'Rourke, S. G. Sherman, S. M. Grieb
Year: 2023
Abstract:

Background: As overdose remains a major public health concern in the United States, it is important to understand the experiences people who inject drugs (PWID) have with overdose. Past experiences during such emergencies are an important determinant of future behavior, including help seeking, which can be lifesaving. Methods: We explored experiences with overdose, using data from 21 in-depth interviews collected from PWID in a rural county in West Virginia (Cabell County). We used an iterative, modified constant comparison approach to synthesize resulting interview data. Results: Participants reported pervasive experiences with overdose, including through their own personal overdose experiences, witnessing others overdose, and losing loved ones to overdose fatalities. Experiencing emotional distress when witnessing an overdose was common among our participants. Many participants reported regularly carrying naloxone and using it to reverse overdoses. Multiple participants described believing the myth that people grow immune to naloxone over time. Concerns about the presence of fentanyl in drugs were also common, with many participants attributing their own and others' overdoses to fentanyl. Conclusions: Our findings have important implications for naloxone access and education, as well as policies and practices to encourage help seeking during overdose events among rural PWID. Participant concerns about fentanyl in the drug supply highlight the need for access to drug checking technologies.

Topic(s):
Opioids & Substance Use See topic collection
,
Healthcare Disparities See topic collection
337
Overdose Prevention and Response Toolkit
Type: Web Resource
Authors: Substance Abuse and Mental Health Services Administration
Year: 2024
Publication Place: Rockville, MD
Topic(s):
Opioids & Substance Use See topic collection
,
Grey Literature See topic collection
Disclaimer:

This grey literature reference is included in the Academy's Literature Collection in keeping with our mission to gather all sources of information on integration. Grey literature is comprised of materials that are not made available through traditional publishing avenues. Often, the information from unpublished resources can be limited and the risk of bias cannot be determined.

338
Overdose prevention in injecting opioid users: the role of substance abuse treatment and training programs
Type: Journal Article
Authors: A. Sarasa-Renedo, A. Espelt, C. Folch, C. Vecino, X. Majo, Y. Castellano, J. Casabona, M. T. Brugal, Redan Study Group
Year: 2014
Publication Place: Spain
Topic(s):
Opioids & Substance Use See topic collection
339
Overdose prevention training with naloxone distribution in a prison in Oslo, Norway: A preliminary study
Type: Journal Article
Authors: Aase Grønlien Petterson, Desiree Madah-Amiri
Year: 2017
Topic(s):
Education & Workforce See topic collection
,
Healthcare Disparities See topic collection
,
Opioids & Substance Use See topic collection
340
Overdose response training and naloxone distribution among rural first responders
Type: Journal Article
Authors: Claire A. Wood, Alex Duello, Phil Horn, Rachel Winograd, Lillie Jackson, Sandra Mayen, Karen Wallace
Year: 2021
Topic(s):
Education & Workforce See topic collection
,
Healthcare Disparities See topic collection
,
Healthcare Policy See topic collection
,
Opioids & Substance Use See topic collection